REATA PHARMACEUTICALS INC (42)

Browse by Contract Category

Contracts

Seventh Supplement to Exclusive License and Supply Agreement, dated as of February 28, 2022 between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 10, 2022)
Employment Agreement by and between the Company and Andrea Loewen, dated as of February 24, 2020 (Filed With SEC on February 28, 2022)
Indemnification Agreement by and between the Company and Andrea Loewen, dated as of February 24, 2020 (Filed With SEC on February 28, 2022)
Notice of Grant of Restricted Stock Units for employees, dated as of December 2, 2020 (Filed With SEC on May 6, 2021)
First Amendment to Lease Agreement, dated as of May 27, 2020 (Filed With SEC on August 10, 2020)
Description of Registrants Securities (Filed With SEC on February 19, 2020)
Amendment No. 1 to Exclusive License Agreement, dated as of April 5, 2022, by and between the KU Center for Technology Commercialization, Inc. and the Registrant, dated as of, as... (Filed With SEC on May 10, 2022)
Employment Agreement by and between the Company and Samina Khan, dated as of July 7, 2020 (Filed With SEC on February 28, 2022)
Indemnification Agreement by and between the Company and Samina Khan, dated as of February 24, 2020 (Filed With SEC on February 28, 2022)
Exclusive Patent License Agreement among the Board of Regents of The University of Texas System, The University of Texas M.D. Anderson Cancer Center, and the Trustees of Dartmouth... (Filed With SEC on February 28, 2022)
Exclusive License Agreement between the Trustees of Dartmouth College and the Registrant, dated as of December 16, 2009, as amended (Filed With SEC on February 28, 2022)
Exclusive License Agreement between the KU Center for Technology Commercialization, Inc. and the Registrant, dated as of September 26, 2014 (Filed With SEC on February 28, 2022)
Exclusive License and Supply Agreement between the Registrant and Kyowa Hakko Kirin Co. Ltd., dated as of December 24, 2009 (Filed With SEC on February 28, 2022)
Amendment No. 2 to the Exclusive License Agreement between the Trustees of Dartmouth College and the Registrant, dated as of August 17, 2021 as amended (Filed With SEC on November 8, 2021)
Amendment No. 2 to the Exclusive Patent License Agreement among the Board of Regents of The University of Texas System, The University of Texas M.D. Anderson Cancer Center, and... (Filed With SEC on November 8, 2021)
Indemnification Agreement by and between the Company and Shamim Ruff, dated as of April 15, 2021 (Filed With SEC on April 15, 2021)
Indemnification Agreement by and between the Company and Christy J. Oliger, dated as of April 15, 2021 (Filed With SEC on April 15, 2021)
Notice of Grant of Restricted Stock Units for director/consultants, dated as of December 2, 2020 (Filed With SEC on March 1, 2021)
Fifth Amended and Restated Non-Employee Director Compensation Policy, dated as of December 2, 2020 (Filed With SEC on March 1, 2021)
Underwriting Agreement, dated December 1, 2020, by and among Reata Pharmaceuticals, Inc. and the Representatives (Filed With SEC on December 3, 2020)
Development and Commercialization Funding Agreement between the Company and BXLS V River L.P, dated as of June 10, 2020 (Filed With SEC on August 10, 2020)
Fourth Amended and Restated Non-Employee Director Compensation Policy, dated as of June 10, 2020 (Filed With SEC on August 10, 2020)
Common Stock Purchase Agreement between the Company and BXLS V River L.P, dated as of June 10, 2020 (Filed With SEC on August 10, 2020)
Indemnification Agreement by and between the Company and Martin W. Edwards, dated as of August 3, 2020 (Filed With SEC on July 31, 2020)
Third Amended and Restated Non-Employee Director and Compensation Policy dated as of December 11, 2019 (Filed With SEC on February 19, 2020)
Denbury Lease Expansion Agreement, dated December 12, 2019 (Filed With SEC on February 19, 2020)
Gateway Lease Expansion Agreement, dated December 12, 2019 (Filed With SEC on February 19, 2020)
Notice of Grant of Restricted Stock Units for employees (Filed With SEC on February 19, 2020)
Underwriting Agreement, dated November 13, 2019, by and among Reata Pharmaceuticals, Inc. and the Representatives (Filed With SEC on November 14, 2019)
Restricted Stock Unit Agreement (Filed With SEC on November 12, 2019)
Indemnification Agreement by and between the Company and Manmeet S. Soni dated August 28, 2019 (Filed With SEC on November 12, 2019)
Employment Agreement by and between the Company and Manmeet S. Soni dated August 28, 2019 (Filed With SEC on November 12, 2019)
Notice of Grant of Restricted Stock Units for employees (Filed With SEC on November 12, 2019)
First Amendment to Amended and Restated Loan and Security Agreement, dated as of October 9, 2019 (Filed With SEC on October 10, 2019)
Amended and Restated License Agreement, dated as of October 9, 2019 (Filed With SEC on October 10, 2019)
Sixth Supplement to Exclusive License and Supply Agreement, dated August 22, 2019, between Reata Pharmaceuticals, Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on August 22, 2019)
Fifth Supplement to Exclusive License and Supply Agreement, dated August 22, 2019, between Reata Pharmaceuticals, Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on August 22, 2019)
Reata Pharmaceuticals, Inc. Second Amended and Restated Long Term Incentive Plan (Filed With SEC on May 9, 2019)
Notice of stock option grant forms for employees and director/consultant (Filed With SEC on May 9, 2019)
Stock Option Agreement (Filed With SEC on May 9, 2019)
Notice of Stock Option Grant forms for employees and director/consultants (Filed With SEC on February 28, 2019)
Second Amended and Restated Non-Employee Director Compensation Policy dated as of December 11, 2018 (Filed With SEC on February 28, 2019)